08.26.25 -- Relationship Equity With CDMOs Is Real, Take It From A Packaging Pro

Join Outsourced Pharma Online on September 3rd at 2pm ET for a virtual panel discussion on overcoming difficulties outsourcing development and manufacturing, how does a biopharma organization (of any size) handle a multi-CDMO coordination. Registration is free for this digital event.

Discover how this Peripheral Blood Mononuclear Cell (PBMC) isolation method can transform CAR-T manufacturing by reducing costs, accelerating timelines, and improving patient accessibility.

Intensified adherent cell culture offers a promising solution to the limitations of traditional suspension culture, with the potential to improve efficiency, reduce costs, and accelerate development.

Manufacturing mRNA products is a complex and challenging process that requires careful consideration at each stage. Learn more about the challenges and intricacies involved.

On this episode of Better Biopharma, Interius BioTherapeutics’ Sianny Christanti and Babu Medi, Ph.D., explain how the company is re-engineering a lentiviral vector to enable INT2104, its off-the-shelf, in vivo CAR T-cell therapy. They discuss the vector's design and its manufacturability, as well as the analytical and regulatory challenges of bringing this first-in-human therapy to the clinic.

Observe as experts highlight innovative tools and strategies advancing the safety of gene editing therapies while addressing off-target effects, regulatory demands, and manufacturing efficiency.

Review a scalable suspension-based Lenti production platform using a proprietary HEK293T clonal cell line and improvement steps to generate commercially viable therapies from concept to patient.

An integrated approach to mRNA drug product manufacturing helps to accelerate drug development, mitigate risks, and ultimately deliver life-changing therapies to patients.

Discover how precision fill/finish processes ensure the safety, sterility, and success of cutting-edge viral vector therapies as they move from production to patients.

Mesenchymal stem cell (MSC) development is accompanied by challenges related to adequate characterization, regulatory adherence, and balancing development considerations.

Learn how high-speed isolator lines enable sterile, scalable manufacturing for complex biologics and injectables with unmatched efficiency and product integrity.

The Alerion Microbubble Cell Separation System outperformed standard magnetic methods in T cell recovery, speed, and scalability — achieving higher cell quality.

Explore one CDMO's ability to apply extensive scientific knowledge in CMC development to set the foundation for later-stage clinical supply and commercialization.

A suspension-based, scalable lentiviral vector production platform enables efficient transition from preclinical stage through commercialization with accelerated timelines and reduced manufacturing costs.

From early development to commercialization, gain comprehensive support in meeting regulatory expectations for characterization, potency, stability, and safety testing.

The ActiCells RUO TARGATT Hypo hiPSC Knock-in Kit (Cat. # AST-9650) is a fast and reliable way to build your allogeneic cell-based medicine.